- Home
- AEMD vs RDHL Comparison
AEMD vs RDHL Comparison
Compare AEMD & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AEMD | RDHL |
|---|---|---|
| Founded | 1984 | 2009 |
| Country | United States | Israel |
| Employees | N/A | 35 |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6M | 4.0M |
| IPO Year | 2008 | 2012 |
Fundamental Metrics
Financial Performance| Metric | AEMD | RDHL |
|---|---|---|
| Price | $2.48 | $0.80 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $15.00 | N/A |
| AVG Volume (30 Days) | 15.1K | ★ 22.5K |
| Earning Date | 02-12-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $381.91 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.31 | $0.71 |
| 52 Week High | $5.89 | $3.31 |
Technical Indicators
Market Signals| Indicator | AEMD | RDHL |
|---|---|---|
| Relative Strength Index (RSI) | 62.78 | 41.73 |
| Support Level | $2.22 | $0.79 |
| Resistance Level | $2.44 | $0.89 |
| Average True Range (ATR) | 0.13 | 0.05 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 83.67 | 51.31 |
Price Performance
Historical ComparisonAbout AEMD Aethlon Medical Inc.
Aethlon Medical Inc is a medical therapeutic company. The company is focused on addressing unmet needs in health and biodefense. The company is focused on the development of Hemopurifier, a clinical-stage therapeutic device designed to combat cancer and eliminate life-threatening viruses from the circulatory system.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.